ChiCTR2300072293: An exploratory study on the first-line treatment of advanced unresectable soft tissue sarcoma with zimberelimab administered in combination with anlotinib and eribulin |
|
|
| Recruiting | 2 | 30 | | zimberelimab administered in combination with anlotinib and eribulin | Sanhuan Cancer Hospital, Chaoyang District, Beijing; Sanhuan Cancer Hospital, selt-funded | soft tissue sarcoma | | | | |
NCT05886634: A Study of Etrumadenant and Zimberelimab in People With Dedifferentiated Liposarcoma |
|
|
| Recruiting | 2 | 25 | US | Etrumadenant, Zimberelimab | Memorial Sloan Kettering Cancer Center | Dedifferentiated Liposarcoma, Soft Tissue Sarcoma, Sarcoma,Soft Tissue, Sarcoma, Recurrent Dedifferentiated Liposarcoma, Unresectable Dedifferentiated Liposarcoma, Metastatic Dedifferentiated Liposarcoma | 05/27 | 05/27 | | |
